US Patent Issued to Betagenon on June 2 for "Thiadiazolone derivatives and their use as AMPK agonists for the treatment of diabetes and related disorders" (Swedish Inventors)

ALEXANDRIA, Va., June 2 -- United States Patent no. 12,643,918, issued on June 2, was assigned to Betagenon AB (Umea, Sweden).

"Thiadiazolone derivatives and their use as AMPK agonists for the treatment of diabetes and related disorders" was invented by Thomas Edlund (Umea, Sweden) and Jacob Westman (Jarlasa, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to a compound of formula I, wherein: R1 is as defined in the specification, or a pharmaceutically acceptable salt or solvate thereof, which compounds are useful in the treatment of a disorder or condition ameliorated by the activation of AMPK, particularly as prodrugs."

The patent was filed on Sept. 30, 2021, under Application ...